Dr. Ramya Raghupathi, MD

Dr. Raghupathi practices at Hospital of the University of Pennsylvania in Philadelphia, Pennsylvania, part of University of Pennsylvania.

Dr. Raghupathi's NPI, 1720334113, was assigned on August 3, 2012. Dr. Raghupathi holds Pennsylvania license MD459526.

Dr. Raghupathi's primary practice is Hospital of the University of Pennsylvania, at 3400 Spruce St, Philadelphia, PA 19104 in Philadelphia County. The practice phone is (215) 662-6289.

Dr. Raghupathi's primary practice is Hospital of the University of Pennsylvania in Philadelphia, Pennsylvania, part of University of Pennsylvania. Dr. Raghupathi is also affiliated with Penn Presbyterian Medical Center. The medical group on file is Penn Medicine Lancaster General Health. Dmand AI also links Dr. Raghupathi to 2 more hospitals and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Raghupathi practices, 4 sites in all. Vendor and product names are available with a free account.

Epilepsy is Dr. Raghupathi's primary specialty in the NPI Registry, under taxonomy code 2084E0001X. Dr. Raghupathi is licensed in Pennsylvania.

CMS data shows 308 Medicare services from Dr. Raghupathi across 6 procedure codes in 2024, for 193 Medicare patients. Medicare paid $28,092 for them.

CMS counts 193 Medicare patients who saw Dr. Raghupathi in 2024. The largest group is 65 to 74, with 72 patients. 74% of them have high cholesterol, and 67% have high blood pressure. 38% are also on Medicaid. Their average risk score is 1.99, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Raghupathi's median patient age at 40, with 53% women.

In 2024, Dr. Raghupathi wrote 1,323 Medicare Part D claims for 207 patients. 79% of them were for generic drugs. CMS names the drug for 1,185 of them, across 23 drugs with 11 or more claims each, at $331,140 in total drug cost. In 2023, CMS named 1,391 claims across 26 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 85 out of 100 for Dr. Raghupathi for performance year 2024, reported as part of a group. Dr. Raghupathi accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Raghupathi as offering telehealth.

Dmand AI links 9 papers to Dr. Raghupathi, published from 2020 to 2025. 2023 was the busiest year, with 3. The most frequent topics are Electroencephalography, Epilepsy and Seizures. Dr. Raghupathi has published most often in Epilepsia. Dr. Raghupathi's most frequent co-authors are Erin Caitlin Conrad, MD, Colin Ellis, MD and Taneeta Mindy Ganguly, MD.

CMS Open Payments shows 59 general payments to Dr. Raghupathi from 13 drug and device companies from 2017 to 2025. Consulting fees make up the largest share, 55% of the total. UCB, Inc. paid the most, $8,631.